Literature DB >> 18598928

Immunotherapeutic potential of oncolytic virotherapy.

Robin J Prestwich, Kevin J Harrington, Richard G Vile, Alan A Melcher.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18598928     DOI： 10.1016/S1470-2045(08)70163-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  8 in total

1.  Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver.

Authors:  Sunil K Geevarghese; David A Geller; Hans A de Haan; Markus Hörer; Anette E Knoll; Axel Mescheder; John Nemunaitis; Tony R Reid; Daniel Y Sze; Kenneth K Tanabe; Hoda Tawfik
Journal:  Hum Gene Ther       Date:  2010-09       Impact factor: 5.695

2.  Oncolytic virus-initiated protective immunity against prostate cancer.

Authors:  Shashi A Gujar; D A Pan; Paola Marcato; Katy A Garant; Patrick W K Lee
Journal:  Mol Ther       Date:  2011-01-18       Impact factor: 11.454

3.  Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy.

Authors:  Yu-Qian Zhang; Ya-Chea Tsai; Archana Monie; T-C Wu; Chien-Fu Hung
Journal:  Mol Ther       Date:  2010-01-19       Impact factor: 11.454

4.  Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells.

Authors:  Laura Menotti; Giordano Nicoletti; Valentina Gatta; Stefania Croci; Lorena Landuzzi; Carla De Giovanni; Patrizia Nanni; Pier-Luigi Lollini; Gabriella Campadelli-Fiume
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-20       Impact factor: 11.205

Review 5.  The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.

Authors:  Robin J Prestwich; Fiona Errington; Rosa M Diaz; Hardev S Pandha; Kevin J Harrington; Alan A Melcher; Richard G Vile
Journal:  Hum Gene Ther       Date:  2009-10       Impact factor: 5.695

6.  Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication.

Authors:  Robin J Prestwich; Elizabeth J Ilett; Fiona Errington; Rosa M Diaz; Lynette P Steele; Tim Kottke; Jill Thompson; Feorillo Galivo; Kevin J Harrington; Hardev S Pandha; Peter J Selby; Richard G Vile; Alan A Melcher
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

Review 7.  Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy.

Authors:  Maxine Bauzon; Terry Hermiston
Journal:  Front Immunol       Date:  2014-02-24       Impact factor: 7.561

Review 8.  Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses.

Authors:  Jennifer Altomonte; Oliver Ebert
Journal:  Microb Biotechnol       Date:  2011-09-19       Impact factor: 5.813
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.